APA (7th ed.) Citation

Akıllı, H., Moore, R., Marth, C., Redondo, T. D., Korach, J., Stillie, A., . . . Makker, V. (2025). 1114P First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): Additional 1-year follow-up results from ENGOT-en9/LEAP-001. Annals of Oncology, 36, S741. https://doi.org/10.1016/j.annonc.2025.08.1751

Chicago Style (17th ed.) Citation

Akıllı, H., et al. "1114P First-line Lenvatinib + Pembrolizumab (L + P) Vs Chemotherapy (CT) for Advanced or Recurrent Endometrial Cancer (EC): Additional 1-year Follow-up Results from ENGOT-en9/LEAP-001." Annals of Oncology 36 (2025): S741. https://doi.org/10.1016/j.annonc.2025.08.1751.

MLA (9th ed.) Citation

Akıllı, H., et al. "1114P First-line Lenvatinib + Pembrolizumab (L + P) Vs Chemotherapy (CT) for Advanced or Recurrent Endometrial Cancer (EC): Additional 1-year Follow-up Results from ENGOT-en9/LEAP-001." Annals of Oncology, vol. 36, 2025, p. S741, https://doi.org/10.1016/j.annonc.2025.08.1751.